-+ 0.00%
-+ 0.00%
-+ 0.00%
vTv Therapeutics to host virtual KOL event on hypoglycemia in type 1 diabetes, cadisegliatin Phase 3 program
Share
Listen to the news
vTv Therapeutics to host virtual KOL event on hypoglycemia in type 1 diabetes, cadisegliatin Phase 3 program
  • vTv Therapeutics will host a virtual key opinion leader event on hypoglycemia in type 1 diabetes on Oct. 20, 2026.
  • Session starts at 2:30 p.m. ET, featuring external experts alongside management discussing cadisegliatin’s Phase 3 CATT1 program.
  • Topline data for the CATT1 trial are expected in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9839901) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending